文献速递肝病

对经活检证实的非酒精性脂肪性肝炎患者验证非酒精性脂肪性肝炎慢性肝病问卷

Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-01-11

该研究基于两项国际3期试验中1667例经活检证实的非酒精性脂肪性肝炎(NASH)患者,在治疗前完成CLDQ-NASH问卷,采用标准患者报告结局工具验证流程评估其信度与效度。结果显示各领域内部一致性良好至优秀(Cronbach's α 0.80–0.94),已知组效度可区分肝硬化、肥胖、精神共病、疲劳及2型糖尿病,与SF-36相应领域相关性高,而疾病特异领域与SF-36不相关。结论认为CLDQ-NASH心理测量学特性优秀。

要点

  • CLDQ-NASH在1667例活检证实NASH患者中显示良好至优秀的内部一致性(Cronbach's α 0.80–0.94)。
  • 已知组效度可区分肝硬化、肥胖、精神共病、疲劳及2型糖尿病(多数P值小于阈值)。
  • 疾病特异领域(腹部症状和担忧)与SF-36不相关(所有rho≤0.50)。

核心结论

  • 通过分析1667例经活检证实的NASH患者数据,验证了CLDQ-NASH具有优秀的心理测量学特性。

研究设计与样本

  • 研究数据来自两项selonsertib国际3期试验(NCT03053050和NCT03053063)中经活检证实的NASH患者,最终分析纳入1667例完成CLDQ-NASH的患者。
  • 患者年龄58±9岁,40%为男性,52%有肝硬化,69%有2型糖尿病;CLDQ-NASH在治疗开始前完成。
  • 采用标准患者报告结局工具验证流程,评估内部一致性和效度。

主要发现

  • CLDQ-NASH各领域Cronbach's α值为0.80至0.94,36个条目中33个条目与自身领域相关性大于0.50。
  • 所有条目均与自身领域相关性最大(区分效度)。
  • 已知组效度显示,量表可区分有无肝硬化(与桥接纤维化相比,除1项外所有P值<.02)、肥胖(除1项外所有P值<.001)、精神共病(所有P值<.0001)、疲劳(所有P值<.001)及2型糖尿病(除1项外所有P值<.01)的NASH患者。
  • 与SF-36相关性最高的领域为:活动领域与躯体功能(rho=0.70)、情绪领域与心理健康(rho=0.72)、疲劳领域与活力(rho=0.75)、全身症状领域与躯体疼痛(rho=0.72),所有P值<.0001。
  • 疾病特异领域腹部症状和担忧与SF-36领域不相关(所有rho≤0.50)。

关键数值与推荐

  • CLDQ-NASH包含36个条目,分为6个领域:腹部症状、活动/精力、情绪健康、疲劳、全身症状和担忧。
  • 内部一致性:Cronbach's α 0.80–0.94;36个条目中33个条目与自身领域相关性>0.50。
  • 已知组效度:肝硬化 vs 桥接纤维化(除1项外所有P<.02)、肥胖(除1项外所有P<.001)、精神共病(所有P<.0001)、疲劳(所有P<.001)、2型糖尿病(除1项外所有P<.01)。
  • 与SF-36相关性:活动-躯体功能 rho=0.70,情绪-心理健康 rho=0.72,疲劳-活力 rho=0.75,全身症状-躯体疼痛 rho=0.72(所有P<.0001);腹部症状和担忧与SF-36所有rho≤0.50。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The chronic liver disease questionnaire for nonalcoholic steatohepatitis (CLDQ-NASH) was developed in a systematic manner for assessment of patient-reported outcomes. This instrument collects data on 36 items grouped into 6 domains: abdominal symptoms, activity/energy, emotional health, fatigue, systemic symptoms, and worry. We aimed to validate the CLDQ-NASH in a large group of patients with NASH. METHODS: We collected data from patients with biopsy-proven NASH enrolled in 2 international phase 3 trials of selonsertib (NCT03053050 and NCT03053063). Our final analysis comprised 1667 patients who completed the CLDQ-NASH (age, 58 ± 9 y; 40% male; 52% with cirrhosis; and 69% with type 2 diabetes). The CLDQ-NASH was administered before treatment initiation. A standard patient-reported outcome instrument validation pipeline with internal consistency and validity assessment was applied. RESULTS: The domains of CLDQ-NASH showed good to excellent internal consistency: the Cronbach's α values were 0.80 to 0.94 and item-to-own-domain correlations were greater than 0.50 for 33 of 36 items. All items correlated to the greatest extent with their own domains (discriminant validity). Known-group validity tests indicated that the instrument consistently discriminated between patients with NASH based on the presence of cirrhosis (vs bridging fibrosis; all but 1 P value < .02), obesity (all but 1 P value < .001), psychiatric comorbidities (all P values < .0001), fatigue (all P values < .001), and type 2 diabetes (all but 1 P value < .01). Of the CLDQ-NASH domains, the highest correlated domains with the Short Form-36 were as follows: physical functioning for activity (rho = 0.70), mental health for emotional (rho = 0.72), vitality for fatigue (rho = 0.75), and body pain for systemic (rho = 0.72) (all P values < .0001). In contrast, the domains of abdominal and worry, which are disease-specific, did not correlate with the domains in the Short Form-36 (all rho ≤ 0.50). CONCLUSIONS: We validated the CLDQ-NASH by an analysis of data from 1667 patients with biopsy-proven NASH enrolled in phase 3 trials, observing excellent psychometric characteristics of the instrument.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Stepanova M, Younossi I, et al. Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2019. PMID: 30639779. doi:10.1016/j.cgh.2019.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。